Novavax says its new Covid-19 vaccine is 49-pct effective against South Africa variant
ECONOMYNEXT – A Coronavirus vaccine by Maryland, USA based Novavax Inc, was shown to be 89.3 percent effective against a new UK variant, and 49 pecent effective against one in South Africa, based on studies in the two countries.
Against the original virus it was 95.6 percent effective in a late stage trial, the firm said in a statement.
In mid-stage study it was found to be 49.3 percent effective against the South Africa variant.
NVX-CoV2373 vaccine “contains a full-length, prefusion spike protein made using Novavax’ recombinant nanoparticle technology and the company’s proprietary saponin-based Matrix-M adjuvant,” the firm said in a statement.
“The purified protein is encoded by the genetic sequence of the SARS-CoV-2 spike (S) protein and is produced in insect cells.
“It can neither cause COVID-19 nor can it replicate, is stable at 2°C to 8°C (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.”
The South African variant has also been found in the US and the report said.
Moderna and Pfizer had also said their versions were less effective against the South Africa version.
Both the UK and South African versions were highly transmissible. (Colombo/Jan29/2021)